Daewoong Pharma - Change In Working Capital

Daewoong Pharma's Fiscal Year is From January To December - All Figures are in KRW, Billions.

The item "Change-In-Working-Capital" stands at -92.35 Billion South Korean Wons for the trailing twelve months (TTM) period ending 09/30/2025.

Daewoong Pharma's third quarter result of -9.15 Billion KRW for the item "Change In Working Capital" represents an increase of 53.86 percent compared to it's second quarter result.

Also, Daewoong Pharma's third quarter result of -9.15 Billion KRW for the item "Change In Working Capital" represents a decrease of -92.56 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Daewoong Pharma's third quarter result of -92.35 Billion KRW for the item "Change In Working Capital" represents a decrease of -5.00 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -9.14 Billion South Korean Wons compared to the value the year prior.
The 1 year change is -9.14 Billion South Korean Wons.
The 3 year change is -45.30 Billion South Korean Wons.
The 5 year change is -116.08 Billion South Korean Wons.

The Serie's long term average value is -20.09 Billion South Korean Wons. It's latest available value, on 09/30/2025, is -72.26 Billion South Korean Wons lower, compared to it's long term average value.
The Serie's change in South Korean Wons from it's minimum value, on 03/31/2025, to it's latest available value, on 09/30/2025, is +6.01 Billion.
The Serie's change in South Korean Wons from it's maximum value, on 09/30/2023, to it's latest available value, on 09/30/2025, is -158.18 Billion.